Patents by Inventor Vibeke W. Stennicke

Vibeke W. Stennicke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
    Patent number: 8981061
    Abstract: Novel activating receptors of the lg super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-?. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: March 17, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Marco Colonna, Axel Bouchon, Rune Salbo, Charlotte Wiberg, Vibeke W. Stennicke, Anette Henriksen, Mette D. Andersen